Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy

Journal of the National Cancer Institute

Volumn 107, Issue 8, 2015, Pages

  Kobold, Sebastian ^a   Grassmann, Simon ^a   Chaloupka, Michael ^a   Lampert, Christopher ^a   Wenk, Susanne ^a   Kraus, Fabian ^a   Rapp, Moritz ^a   Düwell, Peter ^a   Zeng, Yi ^a   Schmollinger, Jan C ^a   Schnurr, Max ^a   Endres, Stefan ^a   Rothenfußer, Simon ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; GAMMA INTERFERON; HYBRID PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; CD274 PROTEIN, MOUSE; EPITOPE; OVALBUMIN; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1;

ADOPTIVE T CELL TRANSFER; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; TUMOR REGRESSION; ANIMAL; CD8+ T LYMPHOCYTE; GENETIC TRANSDUCTION; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PANCREATIC NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD274; ANTIGENS, CD28; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES; IMMUNOSUPPRESSION; INTERFERON-GAMMA; LYMPHOCYTE COUNT; MICE; MICE, TRANSGENIC; OVALBUMIN; PANCREATIC NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 84939448088     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv146     Document Type: Article

References (40)

1. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol. 2011;8(10):577-585.
2. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6(5):383-393.
3. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
4. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-4557.
5. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243-265.
6. Abate-Daga D, Hanada K, Davis JL, et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 2013;122(8):1399-1410.
7. Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246-2259.
8. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201-1217.
9. Ding ZC, Lu X, Yu M, et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T cell responses through the PD-1/PD-L1 axis. Cancer Res. 2014;74(13):3441-3453.
10. Karyampudi L, Lamichhane P, Scheid AD, et al. Accumulation of Memory Precursor CD8 T cells in Regressing Tumors Following Combination Therapy with Vaccine and Anti-PD-1 Antibody. Cancer Res. 2014;74(11):2974-2985.
11. John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636-5646.
12. Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol. 2013;190(9):4899-4909.
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
14. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
15. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863-871.
16. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133-151.
17. Riley JL, June CH. The CD28 family: a T cell rheostat for therapeutic control of T cell activation. Blood. 2005;105(1):13-21.
18. Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945-954.
19. Okazaki T, Maeda A, Nishimura H, et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98(24):13866-13871.
20. Ankri C, Shamalov K, Horovitz-Fried M, et al. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol. 2013;191(8):4121-4129.
21. Prosser ME, Brown CE, Shami AF, et al. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51(3-4):263-272.
22. Boomer JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010;2(8):a002436.
23. Bauer C, Bauernfeind F, Sterzik A, et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut. 2007;56(9):1275-1282.
24. Hernandez-Chacon JA, Li Y, Wu RC, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother. 2011;34(3):236-250.
25. Chacon JA, Wu RC, Sukhumalchandra P, et al. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T cell therapy. PLoS One. 2013;8(4):e60031.
26. Hombach AA, Abken H. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Immunotherapy. 2013;5(7):677-681.
27. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
28. Morales-Kastresana A, Labiano S, Quetglas JI, et al. Better performance of CARs deprived of the PD-1 brake. Clin Cancer Res. 2013;19(20):5546-5548.
29. Shin JH, Park HB, Oh YM, et al. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T cell therapy in murine tumor models. Blood. 2012;119(24):5678-5687.
30. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.
31. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-477.
32. Bauer CA, Kim EY, Marangoni F, et al. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Invest. 2014;124(6):2425-2440.
33. Perna SK, Pagliara D, Mahendravada A, et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T cell inhibition. Clin Cancer Res. 2014;20(1):131-139.
34. Yao X, Ahmadzadeh M, Lu YC, et al. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012;119(24):5688-5696.
35. Hosoi A, Matsushita H, Shimizu K, et al. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int J Cancer. 2014;134(8):1810-1822.
36. Kodumudi KN, Weber A, Sarnaik AA, et al. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol. 2012;189(11):5147-5154.
37. Schietinger A, Philip M, Liu RB, et al. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med. 2010;207(11):2469-2477.
38. Tischer J, Engel N, Fritsch S, et al. Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant. 2014;49(7):895-901.
39. Bachireddy P, Hainz U, Rooney M, et al. Reversal of in situ T cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014;123(9):1412-1421.
40. Chodon T, Comin-Anduix B, Chmielowski B, et al. Adoptive Transfer of MART-1 T Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma. Clin Cancer Res. 2014;20(9):2457-2465.